MG

Murali Gurappa Ramachandrappa

Active Director Director DIN 10914198
DIN 10914198 First appointment Jan 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Murali Gurappa Ramachandrappa

Data last updated:

Murali Gurappa Ramachandrappa is a Director at Medidrogue Pharmaceuticals Private Limited (since 2025). The company operates in Paper.

DIN 10914198
Primary Designation Director
Industry Paper
First Appointment 21 Jan 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director21 Jan 20252025Active

Directorship timeline

Open interactive timeline →
Medidrogue Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Murali Gurappa Ramachandrappa

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Murali Gurappa Ramachandrappa

Murali Gurappa Ramachandrappa currently holds 1 directorship: Medidrogue Pharmaceuticals Private Limited (Director, since 21 Jan 2025).

Murali Gurappa Ramachandrappa was first appointed on 21 Jan 2025 as Director at Medidrogue Pharmaceuticals Private Limited.

The current boards of Murali Gurappa Ramachandrappa's companies include Byrareddy Cheemalagutta Manjunath (Medidrogue Pharmaceuticals Private Limited), Narayana Swamy Chowda Reddy (Medidrogue Pharmaceuticals Private Limited), Narayana Swamy Jagadeesh (Medidrogue Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available